NCT06931340
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06931340
Title Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Acronym ASPIRE
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.